Partial recovery of dopaminergic pathway after graft of adult mesenchymal stem cells in a rat model of Parkinson's disease. - Wikidata - awgldk - TriplyDB

Partial recovery of dopaminergic pathway after graft of adult mesenchymal stem cells in a rat model of Parkinson's disease.

Partial recovery of dopaminergic pathway after graft of adult mesenchymal stem cells in a rat model of Parkinson's disease.

http://www.wikidata.org/entity/Q44095653

about

A Compendium of Preparation and Application of Stem Cells in Parkinson's Disease: Current Status and Future Prospects Increased Understanding of Stem Cell Behavior in Neurodegenerative and Neuromuscular Disorders by Use of Noninvasive Cell Imaging Focus on Extracellular Vesicles: Development of Extracellular Vesicle-Based Therapeutic Systems Stem cell transplantation therapy in Parkinson's disease Mesenchymal stem cells for the treatment of neurodegenerative and psychiatric disorders Multipotent progenitor cells derived from adult peripheral blood of swine have high neurogenic potential in vitro.Intravenous administration of mesenchymal stem cells exerts therapeutic effects on parkinsonian model of rats: focusing on neuroprotective effects of stromal cell-derived factor-1alpha.Impact of the Secretome of Human Mesenchymal Stem Cells on Brain Structure and Animal Behavior in a Rat Model of Parkinson's Disease.Transplantation of neuronal-primed human bone marrow mesenchymal stem cells in hemiparkinsonian rodents.Bone marrow and umbilical cord blood human mesenchymal stem cells: state of the art Mesenchymal stem cells for the treatment of neurodegenerative disease.Dopamine release from transplanted neural stem cells in Parkinsonian rat striatum in vivo.Prenatal exposure to methylphenidate affects the dopamine system and the reactivity to natural reward in adulthood in rats.Phenotypic changes in cultured smooth muscle cells: limitation or opportunity for tissue engineering of hollow organs?Critical aspects of clinical trial design for novel cell and gene therapies.Parkinson's disease and mesenchymal stem cells: potential for cell-based therapy Intracarotid Infusion of Mesenchymal Stem Cells in an Animal Model of Parkinson's Disease, Focusing on Cell Distribution and Neuroprotective and Behavioral Effects.Kinetics of thermally induced heat shock protein 27 and 70 expression by bone marrow-derived mesenchymal stem cells.Allogeneic guinea pig mesenchymal stem cells ameliorate neurological changes in experimental colitis.Updates in the pathophysiological mechanisms of Parkinson's disease: Emerging role of bone marrow mesenchymal stem cells Transplantation of Deprenyl-Induced Tyrosine Hydroxylase-Positive Cells Improves 6-OHDA-Lesion Rat Model of Parkinson's Disease: Behavioral and Immunohistochemical Evaluation.Cell based therapy in Parkinsonism Cellular immune response to intrastriatally implanted allogeneic bone marrow stromal cells in a rat model of Parkinson's disease Cell-based therapies for Parkinson's disease.Autologous stem cells in neurology: is there a future?Mesenchymal stem cells secretome: a new paradigm for central nervous system regeneration?Towards clinical application of mesenchymal stem cells for treatment of neurological diseases of the central nervous system.Biodistribution of mesenchymal stem/stromal cells in a preclinical setting.Preconditioning as a potential strategy for the prevention of Parkinson's disease.The Secretome of Bone Marrow and Wharton Jelly Derived Mesenchymal Stem Cells Induces Differentiation and Neurite Outgrowth in SH-SY5Y Cells.Neurotrophin Signaling and Stem Cells-Implications for Neurodegenerative Diseases and Stem Cell Therapy.Differentiation of Wharton's Jelly-Derived Mesenchymal Stem Cells into Motor Neuron-Like Cells on Three-Dimensional Collagen-Grafted Nanofibers.Retrovirus-mediated transduction of a cytosine deaminase gene preserves the stemness of mesenchymal stem cells.Transplants of adult mesenchymal and neural stem cells provide neuroprotection and behavioral sparing in a transgenic rat model of Huntington's disease.Reversal of dopaminergic degeneration in a parkinsonian rat following micrografting of human bone marrow-derived neural progenitors.Stem cell transplantation for treating Parkinson's disease: Literature analysis based on the Web of Science.Improved dopamine transporter binding activity after bone marrow mesenchymal stem cell transplantation in a rat model of Parkinson's disease: small animal positron emission tomography study with F-18 FP-CIT.Neuroprotective Surgical Strategies in Parkinson's Disease: Role of Preclinical Data.Survival and immunogenicity of mesenchymal stem cells from the green fluorescent protein transgenic rat in the adult rat brain.Functional role of mesenchymal stem cells in the treatment of chronic neurodegenerative diseases.

P2860

Q26746033-4DA0D159-8DD8-487B-83CC-3D191CBF5C15 Q26753150-02F4E6A6-ECEE-4A8B-8167-B73FC25A1B63 Q26767267-1A475A1C-07E4-46DD-93A7-848FE7899B9D Q26778682-62238239-822C-40BF-AA99-C4BA0BC0CE6D Q26801575-2DA33901-EABB-48D9-99F4-CA1CDE684221 Q30503659-4D5A2AA2-6676-495E-B029-1091C091FDDB Q33564990-FFE2FEB6-4E96-4D5D-89B5-590C3536F4BA Q33722420-1CD7D87F-587C-408F-9761-FE13EACABBDE Q33916202-1D34F9C8-2DDC-40DA-B761-095911111564 Q34271229-121A3A9F-0AD9-43EE-AAD8-75E30A9B9B01 Q34473474-FF06A6C5-39F1-4DFC-B4BC-29F44EFA2CDE Q34480963-AD956CE6-30EA-4970-824F-F488C3FC50EC Q35179006-1395AB1B-151D-44CE-9F54-4EB39C043A59 Q35612819-31036872-43CB-4815-8D0A-6D9DE6500B01 Q35664438-C38D0C28-C428-444C-BB7F-BD4FF257917F Q35864178-57F9AA53-848E-4D98-B589-B7D998E656A2 Q35975405-60AB05CD-47BB-49ED-AB2A-8CD764CCFFC7 Q36111475-2E521796-27E0-485A-A549-AE411796EF6B Q36419634-DD238C14-0952-4271-9A19-C40C0F3C6FEB Q36727515-0DD6FF8B-B081-4CE8-9AAB-A17458FD5530 Q36862636-AFE61BC0-E005-48DC-BCF6-FD8633EB9405 Q36908657-CE162831-F9EC-4FED-A6D8-BD293A21E920 Q37236894-1F9FE4AA-FCDA-41B7-8F17-6795BBA96BC7 Q37886149-44F54820-BC4B-42A6-835E-9A5D54E5B102 Q38062482-234682E0-3061-42DC-A218-3C358A261E2A Q38086083-A32AA4F6-9BA9-4B7C-8FA4-C555D066C0DE Q38098448-4EC0C5C8-73A5-47AA-8307-CDDCA7BD8876 Q38162182-72EED44F-94D8-4AAD-BC70-73E8C1D3948D Q38201685-63E295FE-14C1-453B-A7D2-8D4975F13217 Q38964971-3541697D-C804-4BB2-8D71-BF6309D14CCC Q38999345-B255198A-209D-426D-8186-1CABF0A14774 Q39003538-67752F37-B9A2-4498-A747-F1DE20D6BBC2 Q39190753-94459860-8314-464C-BEB4-547004F5A251 Q39368017-2D366E07-BF44-4D78-9CE7-09509AACEF93 Q39792829-072C2987-1B82-4272-AD69-9A6E617A187D Q41360983-E79A2D5B-B529-4E1C-8BDF-C3020D5208CF Q42470263-032C0563-1AA7-41B6-BF07-0C1DF6533197 Q44266420-64AE6994-60F8-4CD4-8B94-F6433934AD51 Q44545162-E8A7107E-D787-4E04-840A-F6A7CD194A74 Q47941437-588DA738-1E7C-41E8-8FAB-212E7BBCF4DC

P2860

Partial recovery of dopaminergic pathway after graft of adult mesenchymal stem cells in a rat model of Parkinson's disease.

http://www.wikidata.org/entity/Q44095653

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年学术文章

@wuu

2008年学术文章

@zh

2008年学术文章

@zh-cn

2008年学术文章

@zh-hans

2008年学术文章

@zh-my

2008年学术文章

@zh-sg

2008年學術文章

@yue

2008年學術文章

@zh-hant

name

Partial recovery of dopaminerg ...... model of Parkinson's disease.

@en

Partial recovery of dopaminerg ...... model of Parkinson's disease.

@nl

type

label

Partial recovery of dopaminerg ...... model of Parkinson's disease.

@en

Partial recovery of dopaminerg ...... model of Parkinson's disease.

@nl

prefLabel

Partial recovery of dopaminerg ...... model of Parkinson's disease.

@en

Partial recovery of dopaminerg ...... model of Parkinson's disease.

@nl

P1433

Q44095653-E09CC635-A9F6-4B57-B307-875D11333DEA

P1476

Q44095653-3AC9228E-4B04-4CD0-9EF7-5C2F8A8F6549

P2093

Q44095653-1E4803AA-8893-47D1-9A39-89AD0B033B64

Q44095653-2FD17CA1-5495-4681-8529-FF576B9AB3C6

Q44095653-69A1B444-E541-4DEC-B477-20DDDB7CC7F8

Q44095653-7FFE8F17-FC4D-48C1-9994-39ABD01E59C0

Q44095653-A15C53A1-2385-44D5-81FF-1177B2B3C330

Q44095653-B9DC4231-3A42-4E80-BFB6-7D5EAF34E3B1

Q44095653-C8AD19DE-4448-4C13-B770-7354B3D1A50C

Q44095653-F0649A50-4DFB-463C-A22C-482F16BB70F3

P304

Q44095653-134A782B-31E2-46C3-8C1C-F0A3C409A9EF

P31

Q44095653-8364B85E-3CAF-4173-A8A4-46BF67AAEC45

P356

Q44095653-E1F6D2A9-C1AF-4E02-80C0-0FDDF9BB5BAA

P433

Q44095653-7C7B03FE-1F9B-4C7B-A6FE-D788ACB27C17

P478

Q44095653-E7CB4986-903F-4BF9-ACBD-4813B528BF9C

P50

Q44095653-3719B5C1-59E2-4B69-A332-DCD2177E3E75

Q44095653-AE3B56E3-B646-426A-AD7A-B856994405AF

P577

Q44095653-20FED6F1-D2DC-4F3D-9CF0-F33C87A1280F

P698

Q44095653-FA8AD2BD-E80C-4EE9-94CD-6DA27AE8AB86

P921

Q44095653-3892A40E-548A-45C0-A479-E8A25EC0F11C

Q44095653-BDA1EF49-DCBB-4A81-AFD1-24913EC63509

P356

J.NEUINT.2008.02.003

P1433

Neurochemistry International

P1476

Partial recovery of dopaminerg ...... model of Parkinson's disease.

@en

P2093

Angélique Rico

http://www.w3.org/2001/XMLSchema#string

Gaëlle Bouchez

http://www.w3.org/2001/XMLSchema#string

Jean-Claude Besnard

http://www.w3.org/2001/XMLSchema#string

Luc Sensebé

http://www.w3.org/2001/XMLSchema#string

Lucette Garreau

http://www.w3.org/2001/XMLSchema#string

Patrick Vourc'h

http://www.w3.org/2001/XMLSchema#string

Pierre Charbord

http://www.w3.org/2001/XMLSchema#string

Sylvie Bodard

http://www.w3.org/2001/XMLSchema#string

P304

1332-1342

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.NEUINT.2008.02.003

http://www.w3.org/2001/XMLSchema#string

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

52

http://www.w3.org/2001/XMLSchema#string

P50

Denis Guilloteau

P577

2008-03-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18372079

http://www.w3.org/2001/XMLSchema#string

P921

Parkinson's disease